Pharvaris (NASDAQ:PHVS) Shares Down 6% - Should You Sell?

Key Points

• Shares fell 6% to about $29.16 on Friday with volume below average, while analysts hold a consensus "Moderate Buy" and a $42.73 average price target.
• Pharvaris missed quarterly EPS reporting ($0.84) vs. ($0.69) expected, and analysts forecast a negative full-year EPS of about -3.19.
• Insiders have been net sellers, offloading 54,426 shares (~$1.58M) in the past three months, though company insiders still own 11.84% of the stock.

Pharvaris N.V. (NASDAQ:PHVS - Get Free Report)'s share price fell 6% during trading on Friday . The company traded as low as $29.09 and last traded at $29.1550. 163,274 shares traded hands during trading, a decline of 14% from the average session volume of 190,164 shares. The stock had previously closed at $31.01.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on the company. Wolfe Research assumed coverage on Pharvaris in a research note on Thursday, April 9th. They issued an "outperform" rating and a $42.00 price objective on the stock. HC Wainwright reaffirmed a "buy" rating and issued a $60.00 price objective on shares of Pharvaris in a research note on Tuesday, March 3rd. Royal Bank Of Canada decreased their price objective on Pharvaris from $52.00 to $51.00 and set an "outperform" rating on the stock in a research note on Monday, April 6th. Wedbush raised their price objective on Pharvaris from $41.00 to $42.00 and gave the stock an "outperform" rating in a research note on Tuesday, April 7th. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Pharvaris in a research note on Tuesday, April 21st. Eleven equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $42.73.

Pharvaris Stock Down 5.1%

The firm has a 50 day moving average price of $27.62 and a 200 day moving average price of $26.03. The stock has a market cap of $1.93 billion, a P/E ratio of -8.74 and a beta of -2.58.

Pharvaris (NASDAQ:PHVS - Get Free Report) last posted its quarterly earnings data on Friday, April 3rd. The company reported ($0.84) EPS for the quarter, missing the consensus estimate of ($0.69) by ($0.15). Equities analysts predict that Pharvaris N.V. will post -3.19 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, CEO Berndt Modig sold 2,292 shares of the stock in a transaction dated Thursday, April 16th. The stock was sold at an average price of $28.60, for a total transaction of $65,551.20. Following the completion of the sale, the chief executive officer owned 139,792 shares in the company, valued at approximately $3,998,051.20. This trade represents a 1.61% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Anne Lesage sold 7,000 shares of the stock in a transaction dated Wednesday, April 22nd. The stock was sold at an average price of $30.05, for a total value of $210,350.00. Following the sale, the insider owned 156,969 shares of the company's stock, valued at $4,716,918.45. This represents a 4.27% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 54,426 shares of company stock worth $1,578,273. Company insiders own 11.84% of the company's stock.

Institutional Trading of Pharvaris

Several institutional investors have recently made changes to their positions in the business. California State Teachers Retirement System grew its position in shares of Pharvaris by 2.2% during the fourth quarter. California State Teachers Retirement System now owns 23,982 shares of the company's stock worth $666,000 after purchasing an additional 520 shares in the last quarter. JPMorgan Chase & Co. grew its position in shares of Pharvaris by 30.6% during the second quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company's stock worth $59,000 after purchasing an additional 783 shares in the last quarter. GF Fund Management CO. LTD. purchased a new stake in shares of Pharvaris during the fourth quarter worth about $35,000. Public Employees Retirement System of Ohio grew its position in shares of Pharvaris by 20.7% during the fourth quarter. Public Employees Retirement System of Ohio now owns 7,569 shares of the company's stock worth $210,000 after purchasing an additional 1,300 shares in the last quarter. Finally, Legal & General Group Plc grew its position in shares of Pharvaris by 17.2% during the second quarter. Legal & General Group Plc now owns 11,550 shares of the company's stock worth $203,000 after purchasing an additional 1,695 shares in the last quarter.

About Pharvaris

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company's core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company's lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.